Research notes

The report maintains a REDUCE rating with an unchanged DCF-based target price of Rs 8,060 and unchanged EPS estimates, while noting expected Q2FY27 revenue growth of 31.3% YoY but a loss at the APAT level.

The report maintains an ADD rating but trims the target price from Rs 1,375 to Rs 1,365 along with minor downward revisions to EPS estimates, using an SOTP valuation approach.

The report upgrades the rating from ADD to BUY while keeping the target price unchanged at Rs 400 and EPS estimates unchanged.

The report maintains a REDUCE rating with an unchanged target price of Rs 580 and unchanged EPS estimates.

The report maintains a BUY rating but cuts the target price from Rs 925 to Rs 790, lowering the target P/E multiple from 28x to 25x and trimming EPS estimates to reflect near-term margin pressures and potential impact of price hikes on consumer affordability.

The report maintains a BUY rating with an unchanged target price of Rs 225 and unchanged EPS estimates.

The report maintains a REDUCE rating with an unchanged target price of Rs 1,530 and unchanged EPS estimates.

The report maintains an ADD rating with an unchanged target price of Rs 1,245 and broadly unchanged EPS estimates, expecting strong Q2FY27 revenue growth of 27.6% YoY.

The report maintains a BUY rating but cuts the target price from Rs 640 to Rs 570, lowering the target P/E multiple from 38x to 35x and trimming EPS estimates to reflect near-term margin pressures and potential impact of price hikes on consumer affordability.

The report maintains a BUY rating with an unchanged target price of Rs 320 and no change in EPS estimates.

The report maintains a REDUCE rating with an unchanged target price of Rs 320 and no change in EPS estimates.

The note lists an open BUY call dated 6-Oct-26 with buy range 734-724.75, stop loss 685 and target 775 (5.8% upside), valid till 20-Oct-26.

The note lists an open BUY call dated 5-Oct-26 with a buy range of 1787-1776, stop loss 1688 and target 1900 (8% upside), valid till 19-Oct-26.

The note says Gabriel India and Faurecia signed a JV agreement to form Faurecia Anand Seating India, with FORVIA holding 50% plus one share.

The note says quarterly revenue rose 79% YoY to Rs 74.3 crore and net profit rose 202.8% YoY to Rs 9.7 crore.

The note says quarterly revenue rose 103.5% YoY to Rs 137 crore, EBITDA margin expanded 550bps to 28.3% and net profit rose 140% to Rs 27.3 crore, with an order book of Rs 2,026 crore.

The note says Adani Power signed a shareholders agreement with Druk Green Power for a 770 MW Chamkharchhu hydropower project in Bhutan, in which it will hold 49%.

The note says IEX traded 39,685 MU of electricity, up 12.7% YoY, with Day Ahead Market clearing price at Rs 5.7/unit, up 46% YoY.

The note says Sun Pharmaceutical established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai.

The note says Q1FY27 revenue rose 72% YoY to Rs 1,581 crore, EBITDA up 45% to Rs 174 crore and net profit up 45% to Rs 87.4 crore, with international revenue at 66%.

The note says Meesho's Content Commerce NMV grew 152% YoY over the 12 months to 31 August 2026 with 1.6 lakh active creators.

The note says Dabur's Q2 update guides to double-digit consolidated revenue and PAT growth with operating margins impacted by inflationary pressures.

The note says Endurance acquired a 100% stake in Italian component maker Fondalpress SpA and parent Anna Milena SpA for EUR 12.34 million.

The note says Max Estates' pre-sales rose 1,246% YoY to about Rs 2,100 crore in Q2FY27, taking H1 pre-sales to about Rs 3,200 crore.

The note says Cyient formed a new integrated business unit, Intelligent Engineering Solutions (IES).